Sandoz' Parlodel
Executive Summary
FDA's Fertility and Maternal Health Drugs Advisory Committee will meet June 1-2 to discuss the use of Parlodel for lactation prevention. At issue is whether any potent drug should be used to suppress postpartum lactation. Sandoz submitted comments Feb. 15 to FDA in response to a citizen petition filed Nov. 29 by Health Research Group and the National Women's Health Network, which called for the deletion of lactation supression labeling from four products, including Parlodel, on the grounds that the natural resolution of lactation does not warrant the risks of reported side effects ("The Pink Sheet" Dec. 5, T&G-12).
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.